Skip to main content
Top
Published in: Journal of General Internal Medicine 5/2017

01-05-2017 | Original Research

Hospitalizations for Chronic Conditions Among Indigenous Australians After Medication Copayment Reductions: the Closing the Gap Copayment Incentive

Authors: Amal N. Trivedi, MD, MPH, Ross Bailie, MBChB, MPhil, MD, Jodie Bailie, BA GradDipEd, Alex Brown, MBBS, PhD, Margaret Kelaher, PhD

Published in: Journal of General Internal Medicine | Issue 5/2017

Login to get access

Abstract

Background

To close health disparities between Indigenous and non-Indigenous Australians, the Australian government in 2010 reduced medication copayments for Indigenous Australians living with, or at risk of, a chronic disease. Patients were registered for this incentive by their general practitioner.

Objective

To assess rates of hospitalizations for chronic conditions among Indigenous Australians before and after copayment reductions.

Design

Observational time-trend study of hospitalizations for chronic conditions sensitive to medication adherence..

Participants

Indigenous persons age 15 years and older in 16 urban, regional, and remote locations. The population ranged from 40,953 in 2009 to 42,651 in 2011.

Main Outcomes

Hospitalizations for diabetes, asthma, chronic obstructive pulmonary disease, hypertension, heart failure, and cardiovascular events.

Key Results

Approximately 22 % of Indigenous persons registered for the medication copayment incentive in the first 18 months of implementation. In areas with rates of incentive uptake exceeding 22 %, the age-standardized rate of hospitalizations for chronic conditions among Indigenous Australians declined from 103.4/1000 (95 % CI 88.8/1000 to 118.0/1000) in 2009 to 60.0/1000 (95 % CI 49.3/1000 to 70.7/1000) in 2011. In areas with below-average uptake of the incentive, we observed non-significant reductions in age-standardized hospitalization rates (from 63.3/1000 [95 % CI 52.9/1000 to 73.7/1000] in 2009 to 58.0/1000 [95 % CI 48.5/1000 to 67.5/1000] in 2011). Among Indigenous Australians, the rate of admission for acute conditions (pneumonia, influenza, urinary tract infection, pyelonephritis, and dehydration) was 38.4/1000 (95 % CI 32.4/1000 to 44.3/1000) in 2009 and 36.2/1000 (95 % CI 30.4/1000 to 41.8/1000) in 2011. Among the non-Indigenous population, we found substantially lower rates of hospitalizations and modest declines from 2009 to 2011.

Conclusions

Though we cannot make causal inferences from the results of this study, we observed marked declines in hospitalizations for chronic conditions among Indigenous Australians following targeted reductions in medication copayments for this population. These declines were largely limited to areas with higher uptake of the copayment incentive and were not observed for admissions related to acute conditions.
Literature
2.
go back to reference Hayman N, Reid PM, King M. Improving health outcomes for Indigenous peoples: what are the challenges? Cochrane Database Syst Rev. 2015;8:ED000104. Hayman N, Reid PM, King M. Improving health outcomes for Indigenous peoples: what are the challenges? Cochrane Database Syst Rev. 2015;8:ED000104.
3.
go back to reference Hill K, Barker B, Vos T. Excess Indigenous mortality: are Indigenous Australians more severely disadvantaged than other Indigenous populations. Int J Epidemiol. 2007;36:580–589.CrossRefPubMed Hill K, Barker B, Vos T. Excess Indigenous mortality: are Indigenous Australians more severely disadvantaged than other Indigenous populations. Int J Epidemiol. 2007;36:580–589.CrossRefPubMed
4.
go back to reference Bramley D, Hebert P, Jackson R, Chassin M. Indigenous disparities in disease-specific mortality, a cross-country comparison: New Zealand, Australia, Canada, and the United States. N Z Med J. 2004;117:U1215.PubMed Bramley D, Hebert P, Jackson R, Chassin M. Indigenous disparities in disease-specific mortality, a cross-country comparison: New Zealand, Australia, Canada, and the United States. N Z Med J. 2004;117:U1215.PubMed
5.
go back to reference Vos T, Barker B, Begg S, Stanley L, Lopez AD. Burden of disease and injury in Aboriginal and Torres Strait Islander Peoples: the Indigenous health gap. Int J Epidemiol. 2009;38:470–477.CrossRefPubMed Vos T, Barker B, Begg S, Stanley L, Lopez AD. Burden of disease and injury in Aboriginal and Torres Strait Islander Peoples: the Indigenous health gap. Int J Epidemiol. 2009;38:470–477.CrossRefPubMed
6.
go back to reference Zhao Y, Dempsey K. Causes of inequality in life expectancy between Indigenous and non-Indigenous people in the Northern Territory, 1981–2000: a decomposition analysis. Med J Aust. 2006;184:490–494.PubMed Zhao Y, Dempsey K. Causes of inequality in life expectancy between Indigenous and non-Indigenous people in the Northern Territory, 1981–2000: a decomposition analysis. Med J Aust. 2006;184:490–494.PubMed
7.
go back to reference Bailie J, Schierhout G, Laycock A, et al. Determinants of access to chronic illness care: a mixed-methods evaluation of a national multifaceted chronic disease package for Indigenous Australians. BMJ Open. 2015;5:e008103.CrossRefPubMedPubMedCentral Bailie J, Schierhout G, Laycock A, et al. Determinants of access to chronic illness care: a mixed-methods evaluation of a national multifaceted chronic disease package for Indigenous Australians. BMJ Open. 2015;5:e008103.CrossRefPubMedPubMedCentral
9.
go back to reference Kelaher M, Dunt D, Taylor-Thompson D, et al. Improving access to medicines among clients of remote area Aboriginal and Torres Strait Islander Health Services. Aust N Z J Public Health. 2006;30:177–183.CrossRefPubMed Kelaher M, Dunt D, Taylor-Thompson D, et al. Improving access to medicines among clients of remote area Aboriginal and Torres Strait Islander Health Services. Aust N Z J Public Health. 2006;30:177–183.CrossRefPubMed
10.
go back to reference Couzos S, Sheedy V, Delaney Thiele D. Improving Aboriginal and Torres Strait Islander people’s access to medicines—the QUMAX program. Med J Aust. 2011;195:62–63.PubMed Couzos S, Sheedy V, Delaney Thiele D. Improving Aboriginal and Torres Strait Islander people’s access to medicines—the QUMAX program. Med J Aust. 2011;195:62–63.PubMed
11.
go back to reference Trivedi AN, Pollack AJ, Britt HC, Miller GC, Harrison C, Kelaher MA. General practitioners prescribing of lipid-lowering medications for Indigenous and non-Indigenous Australians, 2001–2013. Med J Aust. 2015;203(10):407–7.e5.CrossRefPubMed Trivedi AN, Pollack AJ, Britt HC, Miller GC, Harrison C, Kelaher MA. General practitioners prescribing of lipid-lowering medications for Indigenous and non-Indigenous Australians, 2001–2013. Med J Aust. 2015;203(10):407–7.e5.CrossRefPubMed
12.
15.
go back to reference Fay MP, Feuer EJ. Confidence intervals for directly standardized rates: a mthod based on the gamma distribution. Stat Med. 1997;16(7):791–801.CrossRefPubMed Fay MP, Feuer EJ. Confidence intervals for directly standardized rates: a mthod based on the gamma distribution. Stat Med. 1997;16(7):791–801.CrossRefPubMed
17.
go back to reference McWilliams JM, Zaslavsky AM, Huskamp HA. Implementation of Medicare Part D and nondrug medical spending for elderly adults with limited prior drug coverage. JAMA. 2011;306(4):402–409.CrossRefPubMed McWilliams JM, Zaslavsky AM, Huskamp HA. Implementation of Medicare Part D and nondrug medical spending for elderly adults with limited prior drug coverage. JAMA. 2011;306(4):402–409.CrossRefPubMed
19.
go back to reference Encinosa WE, Bernard D, Dor A. Does prescription drug adherence reduce hospitalizations and costs? The case of diabetes. Adv Health Econ Health Serv Res. 2010;22:151–73.CrossRefPubMed Encinosa WE, Bernard D, Dor A. Does prescription drug adherence reduce hospitalizations and costs? The case of diabetes. Adv Health Econ Health Serv Res. 2010;22:151–73.CrossRefPubMed
Metadata
Title
Hospitalizations for Chronic Conditions Among Indigenous Australians After Medication Copayment Reductions: the Closing the Gap Copayment Incentive
Authors
Amal N. Trivedi, MD, MPH
Ross Bailie, MBChB, MPhil, MD
Jodie Bailie, BA GradDipEd
Alex Brown, MBBS, PhD
Margaret Kelaher, PhD
Publication date
01-05-2017
Publisher
Springer US
Published in
Journal of General Internal Medicine / Issue 5/2017
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-016-3912-y

Other articles of this Issue 5/2017

Journal of General Internal Medicine 5/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine